Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Non-Current Assets: 2009-2024

Historic Non-Current Assets for Madrigal Pharmaceuticals (MDGL) over the last 12 years, with Dec 2024 value amounting to $9.3 million.

  • Madrigal Pharmaceuticals' Non-Current Assets rose 64.36% to $15.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.8 million, marking a year-over-year increase of 64.36%. This contributed to the annual value of $9.3 million for FY2024, which is 185.36% up from last year.
  • Latest data reveals that Madrigal Pharmaceuticals reported Non-Current Assets of $9.3 million as of FY2024, which was up 185.36% from $3.3 million recorded in FY2023.
  • In the past 5 years, Madrigal Pharmaceuticals' Non-Current Assets registered a high of $9.3 million during FY2024, and its lowest value of $1.2 million during FY2022.
  • Its 3-year average for Non-Current Assets is $4.6 million, with a median of $3.3 million in 2023.
  • Its Non-Current Assets has fluctuated over the past 5 years, first dropped by 27.00% in 2022, then skyrocketed by 185.36% in 2024.
  • Yearly analysis of 5 years shows Madrigal Pharmaceuticals' Non-Current Assets stood at $1.8 million in 2020, then fell by 10.04% to $1.6 million in 2021, then dropped by 27.00% to $1.2 million in 2022, then spiked by 171.49% to $3.3 million in 2023, then spiked by 185.36% to $9.3 million in 2024.